Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 14/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027341 | 1.00 | BDKRB1 (0.47) | BDKRB1NISCHRORCF10UBE2N | |
| SCHEMBL4032971 | 0.94 | BDKRB1 (0.48) | BDKRB1NISCHRORCUBE2NPAX8 | |
| SCHEMBL4032973 | 0.94 | BDKRB1 (0.48) | BDKRB1NISCHRORCUBE2NPAX8 | |
| SCHEMBL4033954 | 0.87 | BDKRB1 (0.59) | BDKRB1 | |
| SCHEMBL4033952 | 0.87 | BDKRB1 (0.59) | BDKRB1 | |
| SCHEMBL4027335 | 0.86 | BDKRB1 (0.62) | BDKRB1NISCHRORC | |
| SCHEMBL5126811 | 0.82 | BDKRB1 (0.63) | BDKRB1UBE2N | |
| SCHEMBL4030172 | 0.82 | BDKRB1 (0.63) | BDKRB1UBE2N | |
| SCHEMBL4032968 | 0.81 | BDKRB1 (0.65) | BDKRB1NISCHRORCUBE2NPAX8 | |
| SCHEMBL4033075 | 0.81 | BDKRB1 (0.58) | BDKRB1NISCHUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | claimed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | claimed |
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885NISCH 2280/4885RORC 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.